294 related articles for article (PubMed ID: 35531932)
21. Prognosis of patients with Rome IV-defined versus physician-diagnosed irritable bowel syndrome: Longitudinal follow-up study.
Goodoory VC; Craig OF; Gracie DJ; Black CJ; Ford AC
Neurogastroenterol Motil; 2022 Jun; 34(6):e14282. PubMed ID: 34612560
[TBL] [Abstract][Full Text] [Related]
22. What impact do Rome IV criteria have on patients with IBS in China?
Wang B; Zhao W; Zhao C; Jin H; Zhang L; Chen Q; Wang B
Scand J Gastroenterol; 2019 Dec; 54(12):1433-1440. PubMed ID: 31829752
[No Abstract] [Full Text] [Related]
23. Upper gastrointestinal endoscopic findings in functional constipation and irritable bowel syndrome diagnosed using the Rome IV criteria: a cross-sectional survey during a medical check-up in Japan.
Otani K; Watanabe T; Takahashi K; Nadatani Y; Ominami M; Fukunaga S; Hosomi S; Kamata N; Tanaka F; Nagami Y; Taira K; Kimura T; Fukumoto S; Fujiwara Y
BMC Gastroenterol; 2023 May; 23(1):140. PubMed ID: 37138209
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of disorders of gut-brain interaction in the Japanese population in the Rome Foundation Global Epidemiological Study.
Fukudo S; Nakaya K; Muratsubaki T; Nakaya N; Hozawa A; Bangdiwala SI; Palsson OS; Sperber AD; Kanazawa M
Neurogastroenterol Motil; 2023 Jun; 35(6):e14581. PubMed ID: 37093785
[TBL] [Abstract][Full Text] [Related]
25. Quantifying Rome symptoms for diagnosis of the irritable bowel syndrome.
Chang JY; Almazar AE; Richard Locke G; Larson JJ; Atkinson EJ; Talley NJ; Saito YA
Neurogastroenterol Motil; 2018 Sep; 30(9):e13356. PubMed ID: 29701271
[TBL] [Abstract][Full Text] [Related]
26. A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care.
Khasawneh M; Craig OF; Gracie DJ; Black CJ; Ford AC
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3397-3404.e1. PubMed ID: 37302448
[TBL] [Abstract][Full Text] [Related]
27. Impact of Rome IV criteria on the prevalence of post-infection irritable bowel syndrome.
Breen-Lyles M; Decuir M; Byale A; Smith K; Grover M
Neurogastroenterol Motil; 2023 May; 35(5):e14532. PubMed ID: 36633303
[TBL] [Abstract][Full Text] [Related]
28. Irritable bowel syndrome based on Rome IV diagnostic criteria associates with non-motor symptoms of Parkinson's disease.
Tai YC; Liao PH; Leta V; Lin CH; Chaudhuri KR
Parkinsonism Relat Disord; 2023 Aug; 113():105496. PubMed ID: 37385160
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome.
Goodoory VC; Ng CE; Black CJ; Ford AC
Aliment Pharmacol Ther; 2023 May; 57(10):1083-1092. PubMed ID: 36914979
[TBL] [Abstract][Full Text] [Related]
30. The epidemiology and quality of life of functional gastrointestinal disorders according to Rome III vs Rome IV criteria: A cross-sectional study in primary care.
Chuah KH; Beh KH; Mahamad Rappek NA; Mahadeva S
J Dig Dis; 2021 Mar; 22(3):159-166. PubMed ID: 33595169
[TBL] [Abstract][Full Text] [Related]
31. Splitting irritable bowel syndrome: from original Rome to Rome II criteria.
Mearin F; Roset M; Badía X; Balboa A; Baró E; Ponce J; Díaz-Rubio M; Caldwell E; Cucala M; Fueyo A; Talley NJ
Am J Gastroenterol; 2004 Jan; 99(1):122-30. PubMed ID: 14687153
[TBL] [Abstract][Full Text] [Related]
32. Prevalence, overlap, and risk factors for Rome IV functional gastrointestinal disorders among college students in northern India.
Goyal O; Nohria S; Dhaliwal AS; Goyal P; Soni RK; Chhina RS; Sood A
Indian J Gastroenterol; 2021 Apr; 40(2):144-153. PubMed ID: 33226570
[TBL] [Abstract][Full Text] [Related]
33. Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms.
Polster A; Van Oudenhove L; Jones M; Öhman L; Törnblom H; Simrén M
Aliment Pharmacol Ther; 2017 Sep; 46(5):529-539. PubMed ID: 28671338
[TBL] [Abstract][Full Text] [Related]
34. Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study.
Vork L; Weerts ZZRM; Mujagic Z; Kruimel JW; Hesselink MAM; Muris JWM; Keszthelyi D; Jonkers DMAE; Masclee AAM
Neurogastroenterol Motil; 2018 Feb; 30(2):. PubMed ID: 28804974
[TBL] [Abstract][Full Text] [Related]
35. The spectra, symptom profiles and overlap of Rome III functional gastrointestinal disorders in a tertiary center in South China.
Xiong LS; Shi Q; Gong XR; Cui Y; Chen MH
J Dig Dis; 2014 Oct; 15(10):538-44. PubMed ID: 25102919
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.
Black CJ; Yiannakou Y; Guthrie E; West R; Houghton LA; Ford AC
Aliment Pharmacol Ther; 2021 May; 53(10):1126-1137. PubMed ID: 33705578
[TBL] [Abstract][Full Text] [Related]
37. Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?
Fang XC; Fan WJ; Drossman DD; Han SM; Ke MY
World J Gastroenterol; 2022 Sep; 28(33):4861-4874. PubMed ID: 36156921
[TBL] [Abstract][Full Text] [Related]
38. Abdominal Pain Severity Is Mainly Associated with Bloating Severity in Patients with Functional Bowel Disorders and Functional Abdominal Pain.
Deutsch D; Bouchoucha M; Uzan J; Raynaud JJ; Sabate JM; Benamouzig R
Dig Dis Sci; 2022 Jul; 67(7):3026-3035. PubMed ID: 34324087
[TBL] [Abstract][Full Text] [Related]
39. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.
Oka P; Parr H; Barberio B; Black CJ; Savarino EV; Ford AC
Lancet Gastroenterol Hepatol; 2020 Oct; 5(10):908-917. PubMed ID: 32702295
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of irritable bowel syndrome and other functional gastrointestinal disorders in Uruguay.
Guido V; Pontet Y; López V; Olano C
Rev Gastroenterol Mex (Engl Ed); 2024; 89(2):258-264. PubMed ID: 38644084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
